EP3510164A1 - Micro-organismes et procédé de production de lactones et de leurs produits secondaires par conversion de cycloalcanes - Google Patents

Micro-organismes et procédé de production de lactones et de leurs produits secondaires par conversion de cycloalcanes

Info

Publication number
EP3510164A1
EP3510164A1 EP16763271.0A EP16763271A EP3510164A1 EP 3510164 A1 EP3510164 A1 EP 3510164A1 EP 16763271 A EP16763271 A EP 16763271A EP 3510164 A1 EP3510164 A1 EP 3510164A1
Authority
EP
European Patent Office
Prior art keywords
enzyme
seq
microorganism
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16763271.0A
Other languages
German (de)
English (en)
Inventor
Rohan KARANDE
Katja BÜHLER
Diego SALAMANCA VELANDIA
Karl-Heinrich Engesser
Andreas Schmid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum fuer Umweltforschung GmbH UFZ
Original Assignee
Helmholtz Zentrum fuer Umweltforschung GmbH UFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum fuer Umweltforschung GmbH UFZ filed Critical Helmholtz Zentrum fuer Umweltforschung GmbH UFZ
Publication of EP3510164A1 publication Critical patent/EP3510164A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/08—Oxygen as only ring hetero atoms containing a hetero ring of at least seven ring members, e.g. zearalenone, macrolide aglycons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0095—Oxidoreductases (1.) acting on iron-sulfur proteins as donor (1.18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/44—Polycarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01245—Cyclohexanol dehydrogenase (1.1.1.245)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13022—Cyclohexanone monooxygenase (1.14.13.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y118/00—Oxidoreductases acting on iron-sulfur proteins as donors (1.18)
    • C12Y118/01—Oxidoreductases acting on iron-sulfur proteins as donors (1.18) with NAD+ or NADP+ as acceptor (1.18.1)
    • C12Y118/01002—Ferredoxin-NADP+ reductase (1.18.1.2)

Definitions

  • the present invention relates to microorganisms or progeny thereof having biosynthetic capability to convert cycloalkanes and to produce lactones and their secondary products which are aliphatic monomers of large industrial polymers such as ⁇ -hydroxy fatty acid, dicarboxylic acids and ⁇ -amino acids (an analogue of lactams).
  • the invention refers further to the biotechnological production of lactones and their secondary products using the microorganisms or progeny thereof.
  • the cycloalkane such as cyclohexane is mainly used for the industrial production of cyclohexanone, ⁇ -caprolactone, ⁇ -caprolactam, and adipic acid e.g. precursors to nylon. Lactones and ⁇ -hydroxy fatty acids form polyester building blocks whereas dicarboxylic acids and ⁇ -amino acids are applied as polyamide building blocks yielding polymers such as Nylon 4,6; Nylon 4,10; Nylon 5; Nylon 5, 10; Nylon 6; Nylon 6,4; Nylon 6,5; Nylon 6,6 and Nylon 6,10, and polyesters.
  • Polyamides are a class of plastics extensively used as textiles and mechanical parts as they incorporate mechanical strength and durability with chemical resistance.
  • PA-6 Nylon 6
  • PA-66 Nylon 6,6
  • PA-6 Nylon 6
  • PA-66 Nylon 6,6
  • adipic acid Key-monomers for these are adipic acid and 8-caprolactam.
  • the world-wide demand for adipic acid was approx. 2.3 million tons, mainly produced via nitric acid-driven oxidation of cyclohexanol or a mixture of cyclohexanol-cyclohexanone. This process generates significant amounts of nitrous oxide waste.
  • the most common synthetic route used to prepare 8-caprolactam is based on the conversion of cyclohexanone to cyclohexanone oxime. This reaction typically occurs in the presence of hydroxylamine sulfate under pH buffered conditions at 85°C. Subsequently, the oxime is converted to ⁇ -caprolactam by Beckmann rearrangement in the presence of fuming sulfuric acid, which leads to large amounts of salts as by-product.
  • metabolic pathways can be designed in engineered cells or microorganisms to obtain monomers for high-end polymers.
  • the present invention is based, at least in part, on the discovery that lactones and also their secondary products can be directly produced from cycloalkanes. At present bioprocesses converting cycloalkanes are not known. Cycloalkanes (hydrocarbons with a ring-like structure) are readily available and cheap substrates.
  • the present invention provides microorganisms or progeny thereof synthesizing enzymes or enzymatic activities being able to produce lactones and further (when indicated) their secondary products by using cycloalkanes.
  • the inventive microorganism or progeny thereof can convert especially C 5 to Cn - cycloalkanes, preferably cyclohexane.
  • microorganisms or progeny thereof (as host cells) which comprise a biosynthetic pathway to a cyclic alcohol compound and further enzyme activities that convert the cyclic alcohol compound resulting in the production of the corresponding lactones (e.g., ⁇ -caprolactone, ⁇ -valerolactone, 2-oxocanone, 2-oxonanone and oxacycloundecan-2-one, oxacyclododecan-2-one) by using the corresponding cycloalkanes as substrate.
  • lactones e.g., ⁇ -caprolactone, ⁇ -valerolactone, 2-oxocanone, 2-oxonanone and oxacycloundecan-2-one, oxacyclododecan-2-one
  • inventive microorganisms or progeny thereof can comprise nucleic acid sequences encoding an enzyme having an activity that converts the lactone and thereby results in the production of the corresponding ⁇ -hydroxy fatty acid(s) (e.g., 6-hydroxyhexanoic acid) and/or nucleic acid sequences encoding an enzyme having an activity that converts ⁇ - hydroxy fatty acid(s) to dicarboxylic acid(s) (e.g., adipic acid).
  • ⁇ -hydroxy fatty acid(s) e.g., 6-hydroxyhexanoic acid
  • nucleic acid sequences encoding an enzyme having an activity that converts ⁇ - hydroxy fatty acid(s) to dicarboxylic acid(s) (e.g., adipic acid).
  • microorganisms or progeny thereof can comprise nucleic acid sequences encoding an enzyme having an activity that converts the lactone and thereby results in the production of the corresponding co-amino acid(s) (e.g., ⁇ -aminohexanoic acid).
  • enzyme or “enzyme activity” encompass a single enzyme, mixtures comprising one or more enzymes, or enzyme complexes.
  • nucleic acid sequences includes DNA (deoxyribonucleic acids) and RNA (ribonucleic acids) which are able to encode polypeptides having enzymatic activities.
  • a "polypeptide” is a polymer comprising two or more amino acid residues (e.g. a peptide or a protein). The polymer can additionally comprise non-amino acid elements such as labels, quenchers, blocking groups, or the like and can optionally comprise modifications such as glycosylation or the like.
  • the amino acid residues of the polypeptide can be natural or non-natural and can be unsubstituted, unmodified, substituted or modified.
  • the skilled person is well aware of means and methods to determine whether a given polypeptide has the desired enzymatic activity or not and to determine the level of the enzymatic activity of a particular polypeptide or probe in absolute values and/or relative to another polypeptide or probe.
  • the term "progeny” denotes cells and microorganisms which result from proliferation of the microorganisms of the invention and which express the enzymatic pathways as defined in the claims.
  • the microorganism can be a prokaryotic organism, preferably a bacterial cell or algae, more preferably a bacterial cell of the genus Acidovorax, or Pseudomonas, or E.coli; the genus Pseudomonas is more preferred.
  • Even more preferably microorganisms are Acidovorax CHX 100, Pseudomonas taiwanensis VLB 120 or P.
  • taiwanensis VLB120T7 P.putida KT2440, P.putida KT2440 (T7), P. putida GPol, P. fluorescens, P. putida mt-2, P. aeruginosa PAOl, P. putida GPo12, P. taiwanensis VLB120AC, P. taiwanensis VLB 130, P. taiwanensis VLB 140, P. taiwanensis VLB 150, P. taiwanensis VLB 160, P. putida S12, P. acidovorans, P. putida PpS81 , P.
  • P. taiwanensis VLB120 and Acidovorax CHX 100 are the most preferred organisms.
  • microorganisms or progeny thereof are represented which express the following enzymatic pathway:
  • microorganism is genetically modified to express at least one, more than one, either or all of the enzymes E1 , E2, E3, E4, E5, and/or E6.
  • inventive microorganism expresses E1 , E2, E3, E4, E5 and E6.
  • microorganism is genetically modified to express at least one, more than one, either or all of the enzymes E1 , E2, E3, E4, E5, and/or E7.
  • inventive microorganism expresses E1 , E2, E3, E4, E5 and E7.
  • microorganisms or progeny thereof are represented which express the following enzymatic pathway:
  • microorganism is genetically modified to express at least one, more than one, either or all of the enzymes E1 , E2, E3, and/or E4.
  • inventive microorganism expresses E1 , E2, E3 and E4.
  • microorganism catalyzing conversion of said cyclic ketone to the corresponding lactone; wherein the microorganism is genetically modified to express at least one, more than one, either or all of the enzymes E1 , E2, and/or E3.
  • inventive microorganism expresses E1 , E2 and E3.
  • microorganism is genetically modified to express at least one, more than one, either or all of the enzymes E1 and/or E2.
  • inventive microorganism expresses E1 and E2.
  • Preferred microorganisms or progeny thereof of the present invention are represented comprising nucleic acid sequences encoding cytochrome P450 monooxygenase activity as enzyme E1 and nucleic acid sequences encoding an alcohol dehydrogenase activity as enzyme E2. Further the microorganism can comprise nucleic acid sequences encoding a Bayer-Villager type monooxygenase activity as enzyme E3 and/or nucleic acid sequences encoding a lactonase activity as enzyme E4.
  • the present invention can provide microorganisms or progeny thereof comprising additionally nucleic acid sequences encoding co- hydroxy fatty acid dehydrogenases E5 and/or co-oxo fatty acid dehydrogenases E6.
  • the microorganisms or progeny thereof can further comprise nucleic acid sequences encoding a co- transaminase activity as enzyme E7.
  • cytochrome P450 monooxygenase as an enzyme E1 as used herein refers to an enzyme that uses a variety of small and large molecules as substrates in enzymatic reactions. They are, in general, the terminal oxidase enzymes in electron transport chains. CYP enzymes have been identified in all domains of life.
  • cytochrome P450 monooxygenase encompasses the activity of a given polypeptide to catalyse a reaction with at least one cycloalkane as substrate.
  • alcohol dehydrogenase as an enzyme E2 as used herein refers to a group of dehydrogenase enzymes that occur in many organisms and facilitate the interconversion between alcohols and aldehydes or ketones.
  • alcohol dehydrogenases encompasses the activity of a given polypeptide to catalyse a reaction with at least one cyclic alcohol as substrate to the corresponding cyclic ketone.
  • a "Baeyer-Villiger monooxygenase (BVMO)" as an enzyme E3 as used herein refers to a biocatalyst that offer the prospect of high chemo-, regio-, and enantioselectivity in the organic synthesis of lactones or esters from a variety of ketones.
  • Baeyer-Villiger monooxygenase encompasses the activity of a given polypeptide to catalyse a reaction with at least one cyclic ketone as substrate to the corresponding lactone(s).
  • lactonease as an enzyme E4 as used herein refers to a metalloenzyme produced by certain species of bacteria, which targets and converts lactones.
  • lactonease encompass the activity of a given polypeptide to catalyse a reaction with at least one lactone as substrate to the corresponding co-hydroxy fatty acid(s).
  • an "omega-hydroxy fatty acid dehydrogenase” as an enzyme E5 as used herein refers to a group of dehydrogenase enzymes that occur in many organisms and convert linear hydroxy fatty acids.
  • co-hydroxy fatty acid dehydrogenases encompasses the activity of a given polypeptide to catalyse a reaction with at least one ⁇ -hydroxy fatty acid as substrate to the co-oxo fatty acid.
  • an "omega-oxo fatty acid dehydrogenase” as an enzyme E6 as used herein refers to a group of dehydrogenase enzymes that occur in many organisms and convert linear co-oxo fatty acids.
  • co-oxo fatty acid dehydrogenases encompasses the activity of a given polypeptide to catalyse a reaction with at least one co-oxo fatty acid as substrate to the corresponding linear saturated dicarboxylic acid(s).
  • an “omega-transaminase” as an enzyme E7 as used herein refers to an enzyme capable of producing chiral amines.
  • co-transaminase encompasses the activity of a given polypeptide to catalyse a reaction with at least one cyclic lactone as substrate to the corresponding co-aminocarboxylic acid(s).
  • a "co-transaminase” E7 can catalyse a reaction of an co-oxo-fatty acid to the corresponding linear saturated co-aminocarboxylic acid.
  • the cytochrome P450 monooxygenase activity E1 is a cyclohexane cytochrome P450 monooxygenase system which comprises a cytochrome P450 (CYP) activity, a ferredoxin(Fd) activity and a ferredoxin reductase (FdR) activity.
  • the enzyme E1 is a cyclohexane cytochrome P450 monooxygenase system derived from Acidovorax CWX O.
  • the enzyme E1 is classified as a cyclohexane cytochrome P450 monooxygenase system comprising a cytochrome P450 protein ( CHX) with an amino acid sequence of SEQ ID NO: 1 or amino acid sequences which share at least 85% sequence identity, a ferredoxin protein (Fd) with an amino acid sequence of SEQ ID NO: 2 or amino acid sequences which share at least 85% sequence identity and a ferredoxin reductase protein (FdR) with an amino acid sequence of SEQ ID NO: 3 or amino acid sequences which share at least 85% sequence identity.
  • CHX cytochrome P450 protein
  • Fd ferredoxin protein
  • FdR ferredoxin reductase protein
  • Enzyme E2 is preferably a cyclohexanol dehydrogenase (CDH) activity; more preferably enzyme E2 is a cyclohexanol dehydrogenase (CDH) activity derived from Acidovorax CHX 100. Most preferably the enzyme E2 is a cyclohexanol dehydrogenase protein (CDH) with an amino acid sequence of SEQ ID NO: 4 or amino acid sequences which share at least 85% sequence identity.
  • CDH cyclohexanol dehydrogenase activity
  • CDH cyclohexanol dehydrogenase protein
  • Further amino acid sequences E2 can have at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% and even 100% sequence identity to the respective above sequence SEQ ID NO 4 and have the same function.
  • Enzyme E3 is preferably a cyclohexanone monooxygenase (CHXON). More preferably enzyme E3 is a cyclohexanone monooxygenase (CHXON) derived from Acidovorax CHX 100. Most preferably the enzyme E3 is a cyclohexanone monooxygenase protein (CHXON) with an amino acid sequence of SEQ ID NO: 5 or amino acid sequences which share at least 85% sequence identity.
  • CHXON cyclohexanone monooxygenase
  • Further amino acid sequences E3 can have at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% and even 100% sequence identity to the respective above sequences SEQ ID NO 5 and have the same function.
  • Enzyme E4 is preferably a lactonase. More preferably enzyme E4 is an endogenous lactonase or a 1-oxa-2-oxo-cycloheptane lactonase derived from Acidovorax CHX 100. Most preferably the enzyme E4 is a lipase or lactonase protein with an amino acid sequence of SEQ ID NO: 6 or amino acid sequences which share at least 85% sequence identity.
  • Further amino acid sequences E4 can have at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% and even 100% sequence identity to the respective above sequences SEQ ID NO 6 and have the same function.
  • Enzyme E5 is preferably a dehydrogenase. More preferably enzyme E5 is an endogenous dehydrogenase or a 6-hydroxy-hexanoic acid dehydrogenase derived from Acidovorax CHX 100. Most preferably the enzyme E5 is a dehydrogenase protein with an amino acid sequence of SEQ ID NO: 7 or amino acid sequences which share at least 85% sequence identity.
  • Further amino acid sequences E5 can have at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% and even 100% sequence identity to the respective above sequences SEQ ID NO: 7 and have the same function.
  • Enzyme E6 is preferably a dehydrogenase. More preferably enzyme E6 is an endogenous dehydrogenase or a 6-oxo-hexanoic acid dehydrogenase derived from Acidovorax CHX 100. Most preferably the enzyme E6 is a dehydrogenase protein with an amino acid sequence of SEQ ID NO: 8 or amino acid sequences which share at least 85% sequence identity.
  • Further amino acid sequences E6 can have at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% and even 100% sequence identity to the respective above sequences SEQ ID NO: 8 and have the same function.
  • An co-transaminase derived from Chromobacterium violaceum is the preferred enzyme E7; more preferably the enzyme E7 is a co-transaminase with an amino acid sequence of SEQ ID NO: 9 or amino acid sequences which share at least 85% sequence identity.
  • Further amino acid sequences E7 can have at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% and even 100% sequence identity to the respective above sequences SEQ ID NO 9 and have the same function.
  • the invention is not limited to the above exemplified enzymes. Nucleic acid sequences encoding the enzymes having the above described capacity would be routine to screen and these sequences from similar organisms or unrelated organisms as described above may be used in the methods of the invention.
  • the enzyme will be a wild-type enzyme and in other embodiments it will be a mutant or an engineered variant of the wild-type enzyme.
  • the mutant or engineered variants of the wild-type enzymes SEQ ID NO 1 to SEQ ID NO 9 and corresponding polynucleotides encoding such engineered enzymes can be obtained using methods used by those skilled in the art.
  • the engineered enzymes described herein can be obtained by subjecting the naturally occurring polynucleotide encoding the naturally occurring enzymes to mutagenesis and/or directed evolution methods.
  • a preferred microorganism of the present invention according to the disclosure will be engineered to comprise the following nucleic acid sequences:
  • cytochrome P450 enzyme system comprising the monooxygenase (CYP) and the two reductases (Fd and FdR) (Genbank Accession No.: kb686056.1 ), namely:
  • SEQ ID NO: 18 - encoding the monooxygenase (CYP) of SEQ ID NO: 1 .
  • Further nucleic acid sequences can be comprised having at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% and even 100% sequence identity to the above SEQ ID NO: 18 and possess the same properties.
  • SEQ ID NO: 19 - encoding the ferredoxin protein (Fd) of SEQ ID NO: 2 which is part of the electron-transfer chain necessary for cytochrome P450 monooxygenase activity.
  • Further nucleic acid sequences can be comprised having at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% and even 100% sequence identity to the above SEQ ID NO: 19 and possess the same properties.
  • SEQ ID NO: 20 - encoding the ferredoxin reductase protein (FdR) of SEQ ID NO: 3 which is part of the electron-transfer chain necessary for cytochrome P450 monooxygenase activity.
  • Further nucleic acid sequences can be comprised having at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% and even 100% sequence identity to the above SEQ ID NO: 20 and possess the same properties.
  • SEQ ID NO: 21 - encoding the cyclohexanol dehydrogenase (CDH) of SEQ ID NO: 4.
  • Further nucleic acid sequences can be comprised having at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% and even 100% sequence identity to the above SEQ ID NO: 21 and possess the same properties.
  • SEQ ID NO: 22 encoding the cyclohexane monooxygenase (CHXON) of SEQ ID NO: 5.
  • nucleic acid sequences can be comprised having at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% and even 100% sequence identity to the above SEQ ID NO: 22 and possess the same properties.
  • SEQ ID NO: 23 - encoding the lactonase of SEQ ID NO: 6.
  • Further nucleic acid sequences can be comprised having at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% and even 100% sequence identity to the above SEQ ID NO: 23 and possess the same properties.
  • SEQ ID NO: 24 - encoding the 6-hydroxy-hexanoic acid dehydrogenase of SEQ ID NO: 7.
  • Further nucleic acid sequences can be comprised having at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% and even 100% sequence identity to the above SEQ ID NO: 24 and possess the same properties.
  • SEQ ID NO: 25 - encoding the 6-oxo-hexanoic acid dehydrogenase of SEQ ID NO: 8.
  • Further nucleic acid sequences can be comprised having at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% and even 100% sequence identity to the above SEQ ID NO: 25 and possess the same properties.
  • SEQ ID NO: 26 - encoding the ⁇ -transaminase of SEQ ID NO: 9.
  • Further nucleic acid sequences can be used having at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% and even 100% sequence identity to the above SEQ ID NO: 26 and possess the same properties.
  • a nucleic acid sequence (polynucleotide) or polypeptide has a certain percent "sequence identity" to another polynucleotide or polypeptide, meaning that, when aligned, that percentage of bases or amino acids are the same, and in the same relative position, when comparing the two sequences. Sequence similarity can be determined in a number of different manners. To determine sequence identity, sequences can be aligned using the methods and computer programs, including BLAST, available over the world wide web at ncbi.nlm.nih.gov/BLAST. See, e.g., Altschul et al. (1990), J. Mol. Biol. 215:403-10.
  • FASTA Another alignment algorithm is FASTA, available in the Genetics Computing Group (GCG) package, from Madison, Wisconsin, USA, a wholly owned subsidiary of Oxford Molecular Group, Inc.
  • GCG Genetics Computing Group
  • Other techniques for alignment are described in Methods in Enzymology, vol. 266: Computer Methods for Macromolecular Sequence Analysis (1996), ed. Doolittle, Academic Press, Inc., a division of Harcourt Brace & Co., San Diego, California, USA.
  • alignment programs that permit gaps in the sequence.
  • the Smith-Waterman is one type of algorithm that permits gaps in sequence alignments. See Meth. Mol. Biol. 70: 173-187 (1997).
  • the GAP program using the Needleman and Wunsch alignment method can be utilized to align sequences. See J. Mol. Biol. 48: 443-453 (1970).
  • polynucleotide sequence or “nucleic acid sequence” or “gene” used interchangeably herein is said to "encode” a sense or antisense RNA molecule, or RNA silencing or interference molecule or a polypeptide, if the polynucleotide sequence can be transcribed (in spliced or unspliced form) and/or translated into the RNA or polypeptide, or a subsequence thereof.
  • a preferred microorganism or a progeny thereof of the present invention can be one that has been genetically modified with one or more heterologous nucleic acid sequences encoding a CYP450 monooxygenase system E1 , an alcohol dehydrogenase E2, a Bayer-Villager type monooxygenase E3, a lactonase E4, an co-hydroxy fatty acid dehydrogenase E5. an co-oxo fatty acid dehydrogenase E6 and/or also an ( ⁇ transaminase E7.
  • An example of a microorganism of the invention is a microorganism of the genus Pseudomonas that has been genetically modified with a construct comprising heterologous nucleic acid sequences as set forth in SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22 and optionally SEQ ID NO: 23 and/or SEQ ID NO: 24 and/or SEQ ID NO: 25.
  • Such a microorganism of the genus Pseudomonas can produce the intrinsic enzymes lactonase E4 of SEQ ID NO: 6, ⁇ -hydroxy fatty acid dehydrogenase E5 of SEQ ID NO: 7 and/or co-oxo fatty acid dehydrogenase E6 of SEQ ID NO: 8.
  • Such an inventive microorganism is preferably capable of producing ⁇ -caprolactone, 6-hydroxyhexanoic acid and adipic acid.
  • a further example of a microorganism of the present invention is a microorganism of the genus Pseudomonas that has been genetically modified with a construct comprising heterologous nucleic acid sequences as set forth in SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20. SEQ ID NO: 21 , SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24 and SEQ ID NO: 26.
  • Such an inventive microorganism is preferably capable of producing ⁇ -caprolactone, 6-hydroxyhexanoic acid and ⁇ -aminohexanoic acid.
  • a further example of a microorganism of the present invention is a microorganism of the genus Pseudomonas that has been genetically modified with a construct comprising heterologous nucleic acid sequences as set forth in SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21 , SEQ ID NO: 22, and SEQ ID NO: 23.
  • Such an inventive microorganism is preferably capable of producing ⁇ -caprolactone, and 6-hydroxyhexanoic acid.
  • a further example of a microorganism of the present invention is a microorganism of the genus Pseudomonas that has been genetically modified with a construct comprising heterologous nucleic acid sequences as set forth in SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22.
  • Such an inventive microorganism is preferably capable of producing ⁇ -caprolactone.
  • An additional example of a microorganism of the present invention is a microorganism of the genus Pseudomonas that has been genetically modified with a construct comprising heterologous nucleic acid sequences as set forth in SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21 .
  • Such an inventive microorganism is preferably capable of producing cyclohexanone.
  • microorganism of Pseudomonas taiwanensis VLB120 More preferred is a microorganism of Pseudomonas taiwanensis VLB120.
  • a further preferred microorganism of the invention can be genetically engineered Acidovorax CHX100.
  • heterologous nucleic acid refers to a nucleic acid wherein at least one of the following is true: (a) the nucleic acid is foreign ("exogenous") to (i.e., not naturally found in) a given host microorganism; (b) the nucleic acid comprises two or more nucleotide sequences that are not found in the same relationship to each other in nature, e.g., the nucleic acid is recombinant.
  • heterologous nucleic acid is a nucleic acid encoding CYP, where a host microorganism that does not normally produce CYP is genetically modified with the nucleic acid encoding CYP: because CYP-encoding nucleic acids are not naturally found in the host microorganism, the nucleic acid is heterologous to the genetically modified microorganism.
  • Recombinant means that a particular nucleic acid (DNA or RNA) is the product of various combinations of cloning, restriction, and/or ligation steps resulting in a construct having a structural coding or non-coding sequence distinguishable from endogenous nucleic acids found in natural systems.
  • DNA sequences encoding the structural coding sequence can be assembled from cDNA fragments and short oligonucleotide linkers, or from a series of synthetic oligonucleotides, to provide a synthetic nucleic acid which is capable of being expressed from a recombinant transcriptional unit contained in a cell or in a cell-free transcription and translation system.
  • sequences can be provided in the form of an open reading frame uninterrupted by internal non-translated sequences, or introns, which are typically present in eukaryotic genes.
  • Genomic DNA comprising the relevant sequences can also be used in the formation of a recombinant gene or transcriptional unit. Sequences of non-translated DNA may be present 5' or 3' from the open reading frame, where such sequences do not interfere with manipulation or expression of the coding regions, and may indeed act to modulate production of a desired product by various mechanisms (see “DNA regulatory sequences", below).
  • the term "recombinant" polynucleotide or nucleic acid refers to one which is not naturally occurring, e.g., is made by the artificial combination of two otherwise separated segments of sequence through human intervention.
  • This artificial combination is often accomplished by either chemical synthesis means, or by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques. Such is usually done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site. Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a desired combination of functions.
  • construct is meant a recombinant nucleic acid, generally recombinant DNA, which has been generated for the purpose of the expression of a specific nucleotide sequence(s), or is to be used in the construction of other recombinant nucleotide sequences.
  • the invented technology provides especially a biocatalytic pathway for the production of ⁇ -caprolactone, 6-hydroxyhexanoic acid and adipic acid and optionally co- aminohexanoic acid by using a microorganism of Pseudomonas taiwanensis VLB120.
  • This microorganism of the present invention comprises heterologous enzymes from Acidovorax CHX100 coupled to its intrinsic occurring enzymes.
  • heterologous enzymes include the cyclohexane cytochrome P450 monooxygenase (CHX) E1 from Acidovorax CHX 100, the cyclohexanol dehydrogenase (CDH) E2 from Acidovorax CHX100 and the cyclohexanone monooxygenase (CHXON) E3 from Acidovorax CHX100.
  • CHX cyclohexane cytochrome P450 monooxygenase
  • CDH cyclohexanol dehydrogenase
  • CHXON cyclohexanone monooxygenase
  • heterologous enzymes of Pseudomonas taiwanensis VLB120 can optionally comprise the co-transaminase E7 of Chromobacterium violaceum.
  • the method to produce the inventive microorganisms is characterized by transformation of the microorganism with at least one of an expression cassette of above and/or a vector of above.
  • the methods are known to the skilled person.
  • To generate a subject genetically modified microorganism one or more nucleic acid sequences encoding an desired enzyme(s) is introduced stably or transiently into the microorganism, using established techniques, including, but not limited to, electroporation, calcium phosphate precipitation, DEAE-dextran mediated transfection, liposome-mediated transfection, and the like.
  • a nucleic acid will generally further include a selectable marker, e.g., any of several well-known selectable markers such as neomycin resistance, ampicillin resistance, tetracycline resistance, chloramphenicol resistance, kanamycin resistance, and the like.
  • a selectable marker e.g., any of several well-known selectable markers such as neomycin resistance, ampicillin resistance, tetracycline resistance, chloramphenicol resistance, kanamycin resistance, and the like.
  • transformation refers to a permanent or transient genetic change induced in a cell of the microorganism following introduction of new nucleic acid (i.e., DNA exogenous to the microorganism cell).
  • Genetic change can be accomplished either by incorporation of the new DNA into the genome of the microorganism, or by transient or stable maintenance of the new DNA as an episomal element.
  • permanent changes can be introduced into the chromosome or via extrachromosomal elements such as plasmids and expression vectors, which may contain one or more selectable markers to aid in their maintenance in the recombinant host microorganism cell of invention.
  • a nucleic acid is hybridizable to another nucleic acid, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid can anneal to the other nucleic acid under the appropriate conditions of temperature and solution ionic strength.
  • Hybridization and washing conditions are well known and exemplified in Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (1989), particularly Chapter 1 1 and Table 1 1.1 therein: and Sambrook, J. and Russell, W., Molecular Cloning: A Laboratory Manual, Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (2001 ).
  • the present invention provides also an expression cassette for the manufacture of a microorganism of the invention, wherein the expression cassette comprises the nucleic acid sequences encoding the desired enzymes.
  • the expression cassette can comprise nucleic acid sequences encoding at least two of enzymes E1 , E2, E3, E4, E5, and E6.
  • the expression cassette Preferably comprises the expression cassette nucleic acid sequences encoding at least three of the enzymes E1 , E2, E3, E4, E5, and E6; more preferably the enzymes E1 , E2 and E3.
  • the expression cassette can comprise nucleic acid sequences encoding enzyme E1 with amino acid sequences of SEQ ID NO: 1 and 2 and 3, enzyme E2 with an amino acid sequence of SEQ ID NO: 4, enzyme E3 with an amino acid sequence of SEQ ID NO: 5, enzyme E4 with an amino acid sequence of SEQ ID NO: 6, enzyme E5 with an amino acid sequence of SEQ ID NO: 7, and enzyme E6 with an amino acid sequence of SEQ ID NO: 8.
  • an inventive expression cassette can comprises a nucleic acid sequence encoding at least two of enzymes E1 , E2, E3, and E4; preferably at least three of the enzymes E1 , E2, E3, and E4; even more preferably enzyme E1 with an amino acid sequence of SEQ ID NO: 1 , 2 and 3, enzyme E2 with an amino acid sequence of SEQ ID NO: 4, enzyme E3 with an amino acid sequence of SEQ ID NO: 5, enzyme E4 with an amino acid sequence of SEQ ID NO: 6.
  • an expression cassette for the manufacture of an inventive microorganism can comprise a nucleic acid sequence encoding at least two of enzymes E1 , E2, and E3; even more preferably enzyme E1 with an amino acid sequence of SEQ ID NO: 1 , 2 and 3, enzyme E2 with an amino acid sequence of SEQ ID NO: 4, enzyme E3 with an amino acid sequence of SEQ ID NO: 5.
  • an expression cassette for the manufacture of an inventive microorganism can comprise a nucleic acid sequence encoding at least two of enzymes E1 and E2; even more preferably enzyme E1 with an amino acid sequence of SEQ ID NO: 1 , 2 and 3, enzyme E2 with an amino acid sequence of SEQ ID NO: 4.
  • an expression cassette for the manufacture of a microorganism of invention comprises a nucleic acid sequence encoding at least two of enzymes E1 , E2, E3, E4, E5, and E7; preferably at least three of the enzymes E1 , E2, E3, E4, E5, and E7, preferably enzymes E1 , E2 and E3.
  • enzyme E1 with an amino acid sequence of SEQ ID NO: 1 , 2 and 3 enzyme E2 with an amino acid sequence of SEQ ID NO: 4, enzyme E3 with an amino acid sequence of SEQ ID NO: 5, enzyme E4 with an amino acid sequence of SEQ ID NO: 6, enzyme E5 with an amino acid sequence of SEQ ID NO: 7, and enzyme E7 with an amino acid sequence of SEQ ID NO: 9 or nucleic acid sequences encoding enzyme E1 with an amino acid sequence of SEQ ID NO: 1 , 2 and 3, enzyme E2 with an amino acid sequence of SEQ ID NO: 4, enzyme E3 with an amino acid sequence of SEQ ID NO: 5, and enzyme E7 with an amino acid sequence of SEQ ID NO: 9.
  • Subject matter of the invention is also a vector comprising an above described expression cassette.
  • An "expression cassette” is a linear or cyclic, single or double stranded nucleic acid construct, e.g. as a part of a vector, such as a plasmid, a viral vector, etc., capable of producing transcripts and, potentially, polypeptides encoded by a polynucleotide sequence.
  • An expression cassette is capable of producing transcripts in an exogenous cell, e.g. a bacterial cell, in vivo or in vitro. Expression of a product can be either constitutive or inducer dependent, e.g. on the promoter selected. Antisense, sense or RNA interference or silencing configurations that are not or cannot be translated are expressly included by this definition.
  • a promoter In the context of an expression cassette, a promoter is said to be "operably linked” or “functionally linked” to a polynucleotide sequence if it is capable of regulating expression of the associated polynucleotide sequence.
  • the term also applies to alternative exogenous gene constructs, such as expressed or integrated transgenes.
  • the term operably or functionally linked applies equally to alternative or additional transcriptional regulatory sequences such as enhancers, associated with a polynucleotide sequence.
  • vector refers to the means by which a nucleic acid can be propagated and/or transferred between organisms, cells, or cellular components.
  • Vectors include plasmids, viruses, bacteriophage, pro-viruses, phagemids, transposons, and artificial chromosomes, and the like, that replicate autonomously or can integrate into a chromosome of a host cell.
  • a vector can also be a naked RNA polynucleotide, a naked DNA polynucleotide, a polynucleotide composed of both DNA and RNA within the same strand, a poly-lysine-conjugated DNA or RNA, a peptide-conjugated DNA or RNA, a liposome- conjugated DNA, or the like, that are not autonomously replicating.
  • “Expression” means transcription of DNA into RNA (optionally including modification of the RNA, e.g. splicing), translation of RNA into a polypeptide (possibly including subsequent modification of the polypeptide, e.g. posttranslational modification), or both transcription and translation, as indicated by the context.
  • the disclosure relates to a method for making lactones and/or their secondary products comprising providing a microorganism as set forth above and transformed with nucleic acid sequences encoding the enzymes E1 , E2, E3, E4, E5, E6 and/or E7.
  • the microorganism is cultured under sufficient culture conditions in the presence of a carbon source to promote the gene expression of the enzymes and the production of lactones and/or their secondary products like hydroxylic acids, ⁇ - ⁇ acids, and/or linear saturated dicarboxylic acids and/or co-aminocarboxylic acid in the presence of a cycloalkane.
  • the method for the production of lactones and/or their secondary products from cyclic alkanes comprises the step of:
  • the culturing is performed in a medium and under conditions appropriate to allow for growth of said microorganism; preferably the culture of the mixture of microorganism and cycloalkane is performed in a culture medium containing the necessary growth nutrients and the cycloalkane either in solution or as an organic liquid phase or as an organic gaseous phase, which enable the cellular catalyst to form lactones, co-hydroxy fatty acid co-oxo acids, and linear saturated dicarboxylic acids and optionally co-aminocarboxylic acid.
  • a cell stock of a microorganism of the present invention was taken and incubated.
  • the biotransformation was initiated by adding respective cycloalkanes.
  • the reaction was stopped for example by adding of ice cold diethyl ether containing decane as internal standard to an equal amount of the reaction mixture phase. Both phases were mixed on a vortex for product extraction and then centrifuged to separate phases.
  • the ether phase was dried over anhydrous Na 2 S0 4 and analyzed by gas chromatography.
  • HPLC High pressure liquid chromatography
  • the reaction is preferably transforming C 5 to C-n - cycloalkanes as the substrate using one whole cell of the microorganism of invention especially in aqueous medium.
  • This single cell reactions together with the increased kinetics of the enzymes and can occur at ambient conditions utilizing molecular oxygen (e.g. from air) as oxidant, without dangerous chemicals, and significantly reduces waste and emissions.
  • the culture of the mixture of microorganism and cycloalkane can be performed in a bioreactor, in a stirred tank, or in a capillary micro-reactor. Stirred tank is the most preferred reactor format.
  • the microorganism can be provided as immobilized biofilm. Biofilms offers several advantages compared to their suspended counterpart as they present a self-immobilizing, self-regenerating biocatalyst format. In addition they are resistant against many otherwise toxic chemical substances and can be operated for long term with activities ranging from days to months
  • the method comprises: (i) culturing in a suitable medium and in presence of cyclohexane a Pseudomonas taiwanensis VLB120 DCi genetically modified to produce heterologous cytochrome P450 enzyme system (CHX) comprising the monooxygenase (CYP) and the two reductases (Fd and FdR), cyclohexane monooxygenase (CHXON) and cyclohexanol dehydrogenase, and wherein the genetically modified Pseudomonas taiwanensis VLB120 cell is further genetically modified or able to produce one or more additional enzymes like e.g.: a iactonase being 1 -oxa-2- oxo-cycloheptane Iactonase or others having at least 85%, at least 88%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 9
  • the preferred inventive microorganisms produce ⁇ -caprolactone, 6-hydroxyhexanoic acid, adipic acid and/or ⁇ -aminohexanoic acid by using cyclohexane as cycloalkane in good amounts.
  • the current invention provides a method, which includes microorganism culturing, expression of exogenous nucleic acids encoding the enzymes E1 , E2, E3, E4, E5, E6 and/or E7 in a sufficient amount to produce respective products such as lactones, ⁇ -hydroxy fatty acid, and linear saturated dicarboxylic or co-aminocarboxylic acid from corresponding cyclic alkanes, and reaction conditions for biotransformations yielding the desired products.
  • this biocatalytic transformation of the preferred used cyclohexane catalyzed by the inventive catalyst allows the synthesis of the three key products caprolactone, 6- hydroxyhexanoic acid and adipic acid as central monomers for large polymers by using the inventive microorganism Pseudomonas taiwanensis VLB120 comprising the heterologous enzymes cyclohexane cytochrome P450 monooxygenase (CHX) E1 , the cyclohexanol dehydrogenase (CDH) E2 and the cyclohexanone monooxygenase (CHXON) E3 from Acidovorax CWX O.
  • inventive microorganism Pseudomonas taiwanensis VLB120 comprising the heterologous enzymes cyclohexane cytochrome P450 monooxygenase (CHX) E1 , the cyclohexanol dehydrogenas
  • heterologous enzyme ⁇ -transaminase E7 from Chromobacterium violaceum in Pseudomonas taiwanensis VLB120T7 results in ⁇ - aminohexanoic acid as product in addition to caprolactone.
  • Figure 1 Construction of plasmid pCom10_capro encoding the respective recombinant genes from Acidovorax CHX100: CypP450 enzyme system (CHX): Cytochrome P450 monooxygenase (CYP) with the corresponding Fd:Ferredoxin FdR: NADH:Ferredoxin reductase, CHXON: Bayer- Villiger type cyclohexanone monooxygenase, and CDH: cyclohexanol dehydrogenase
  • CHX100 CypP450 enzyme system
  • CYP Cytochrome P450 monooxygenase
  • FdR NADH:Ferredoxin reductase
  • CHXON Bayer- Villiger type cyclohexanone monooxygenase
  • CDH cyclohexanol dehydrogenase
  • Figure 2 Synthesis of the recombinant enzymes encoded by pCom10_capro in P. taiwanensis VLB120 visualized via SDS-PAGE. Respective enzymes are marked with the arrows.
  • CHXON cyclohexanone monooxygenase
  • CYP Cytochrome P450 monooxygenase
  • CDH cyclohexanol dehydrogenase.
  • Figure 3 Product profile of the three main products ⁇ -caprolactone, adipic acid, and 6- hydroxyhexanoic acid in a resting cell assay.
  • Figure 4 GC data for biotransformation of cyclopentane, cyclohexane, cycloheptane and cyclooctane to ⁇ -Valerolactone, ⁇ -caprolactone, oxocan-2-one and oxonan-2-one, respectively.
  • Figure 5 GC data for biotransformation of cyclodecane to oxacycloundecan-2-one.
  • Figure 6 LC-MS data of adipic acid and 6-hydrohexanoic acid formation from cyclohexane biotransformation.
  • Figure 7 GC-MS data of ⁇ -Va I era lactone formation from cyclopentane biotransformation.
  • Figure 8 GC-MS data of epsilon-caprolactone formation from cyclohexane biotransformation.
  • Figure 9 GC-MS data of oxocan-2-one formation from cycloheptane biotransformation.
  • Figure 10 GC-MS data of oxonan-2-one formation from cyclooctane biotransformation.
  • Figure 11 GC-MS data of oxacycloundecan-2-one formation from cyclodecane biotransformation.
  • Figure 12 GC-MS data of oxacyclododecan-2-one formation from cycloundecane biotransformation.
  • Cloning strategy The construction of pCom10_capro plasmid, the genes coding for the Cytochrome P450 enzyme complex (chx), cyclohexanol dehydrogenase enzyme (cdh) and cyclohexanone monooxygenase (chxon) was conducted in several steps.
  • pCom10_CHX plasmid was constructed by amplifying cytochrome P450 monooxygenase (CYP) and the two reductases (Fd and FdR) genes from the genomic DNA of Acidovorax CHX100 by polymerase chain reaction PCR (Sambrook and Russel 2001 ) using Phusion high fidelity polymerase (Life Technologies GmbH, Darmstadt, Germany) and the primers (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) given in Table 1. The resulting PCR products were cloned into the pCom10 backbone via restriction sites Ndel and Ascl, respectively, yielding plasmid pCom10_chx. The product was introduced into E.coli DH5a or P.
  • CYP cytochrome P450 monooxygenase
  • Fd and FdR two reductases
  • cyclohexanol dehydrogenase (cdh) and cyclohexanone monooxygenase (chxon) have been coupled on plasmid pCom10_chxon_cdh.
  • Respective genes have been amplified from the genomic DNA of Acidovorax CHX100 by standard polymerase chain reaction PCR (Sambrook and Russel 2001 ). Primers have been are listed in Table 1. Subsequently the resulting PCR products were cloned into the pCom10 backbone via restriction sites Ascll/Hindlll and Ndel/Ascl, respectively, yielding plasmid pCom10_chxon_cdh. This was introduced into P.
  • pCom10_chxon_cdh was isolated from the obtained transformants. Correct insertion of the genes was verified using restriction digest analysis and PCR. To couple chxon_cdh to the existing pCom10_CHX restriction sites needed to be adapted. This was accomplished via PCR using degenerated primers carrying the respective sequences (Table 1 ). Finally, chxon_cdh encoding the dehydrogenase and the BVMO were coupled to chx located on pCom10_CHX using standard cloning procedures. The resulting plasmid pCom10_Capro was introduced into P.
  • the desired plasmid was isolated from obtained transformants. Correct insertion of the genes was verified using restriction digest analysis and PCR. The plasmid map is given in the supporting information.
  • the gene sequence for Cytochrome P450 enzyme system comprising the monooxygenase (CYP) and the two reductases (Fd and FdR) is represented by SEQ ID NO 18, 19 and 20.
  • Table 1 Primers used for cloning respective genes
  • Microbial strains, plasmids and related cultivation and transformation methods All organisms used have been cultivated in Luria-Bertani (LB) medium (DSMZ_medium 381 ) or M9*-medium (DSMZ_medium 382) supplemented with 0.5% (w/v) citrate as a carbon source, US* trace elements (Emmerling et al. 2002, J. Bacteriol. 184:152), and kanamycin 50 ⁇ g mL "1 .
  • Pre- cultures were grown overnight in 5-10 mL LB-medium or M9*-medium in a horizontal shaker (30°C and 200 rpm, Multitron, Infors HT, Bottmingen, Switzerland).
  • Figure 1 shows the construction of plasmid pCom10_capro. b) Transformation of the plasmid into P. taiwanensis VLB 120
  • the plasmid was introduced into P. taiwanensis VLB120 using electroporation (2500 V, Equibio EasyjecT Prima, Kent, UK). All transformation methods were performed as described in Sambrook and Russell, 2001.
  • Biotransformation of cycloalkanes Cells were grown on M9* mineral media containing 0.5% (w/v) citrate to an OD 450 of 0.9 to 1.0 and then induced by the addition of (0,025% v/v) dicyclopropylketone (DCPK). During growth, cells were sampled after each hour for SDS PAGE. After 5-6 h of induction, cells were harvested by centrifugation (Thermo Electron Corporation, Langenselbold, Germany) at 20°C, 4595 g, 15 min, washed and re-suspended in 100 mM of Kpi buffer pH 7.4 supplemented with 1 % of citrate to a cell concentration of 0.5-2.0 g C Dw L ⁇ .
  • DCPK dicyclopropylketone
  • This cell stock (working volume mentioned wherever necessary) was distributed in baffled Erienmeyer flasks with the screw caps and incubated in a rotary shaker at 30°C and 300 rpm for 10 min.
  • the biotransformation was initiated by adding cycloalkanes (5 to 10 mM) to the respective flasks.
  • reaction was stopped by adding 1 ml. of ice cold diethyl ether containing 0.2 mM decane as internal standard to an equal amount of the reaction mixture phase. Both phases were mixed for 2 min on a vortex for product extraction and then centrifuged (13000 rpm; 2 min) to separate phases. The ether phase was dried over anhydrous Na2S04 and analyzed by gas chromatography.
  • HPLC high pressure liquid chromatography
  • the detection was based using flame ionization detector (FID).
  • FID flame ionization detector
  • GC-MS analysis were performed using by ISQTM LT Single Quadrupol GC-MS-System (Thermo Scientific, Waltham, USA) equipped with a TG-5MS GC Column (30 ⁇ ⁇ 0.25 ⁇ ⁇ 0.25 ⁇ ) (Thermo Scientific, Waltham, USA). The temperature profile is as described above.
  • 6-hydroxyhexanoic acid, 8-hydroxyoctanoic acid, 10-hydroxydecanoic acid were determined by HPLC Dionex Ultimate 3000 (Thermo Scientific, Waltham, USA) equipped with Acclaim® OA column (Thermo Scientific, Waltham, USA).
  • Mobile phase A consisted of 10 mM sodium sulfate containing 0.1 % (v/v) formic acid.
  • Acetonitrile was used as mobile phase B.
  • 10- 20 ⁇ _ of sample was injected, while flow and column temperature was kept constant at 0.34 mL/min and 30°C, respectively. Detection was accomplished by using a UV spectrometer. Flow profile was: 5%B for 3 min, 5 to 80%B in 17 min, 80-5%B in 5 min and 5%B for 5 min.
  • Mass spectrometer QTRAP 5500 (Sciex, Toronto, CAN), source temperature 450°C and by using positive electrospray ionization +5 kV.
  • Figure 3 shows the product profile. Average product concentrations of 0.5 to 0.6 g/L for caprolactone (0.1 g/L/h), 0.2 to 0.25 g/L for 6-hydroxyhexanoic acid (0.01 g/L/h), 0.02 g/L adipic acid were achieved.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des micro-organismes ou leur descendance présentant une capacité de biosynthèse pour convertir des cycloalcanes et pour produire des lactones à l'aide d'un complexe composé de cytochrome P450 monooxygénase, de deux réductases de ferrédoxine (Fd) et de ferrédoxine réductase (FdR) conjointement avec une alcool (cyclohexanol) déshydrogénase et une monooxygénase de type Bayer-Villager (cyclohexanone) ; l'ensemble à partir d'Acidovorax CHX 100. En outre, des produits secondaires peuvent être produits qui sont des monomères aliphatiques de grands polymères industriels tels qu'un acide gras w-hydroxy, des acides dicarboxyliques et des acides aminés w (un analogue des lactames). L'invention concerne en outre la production biotechnologique de lactones et de leurs produits secondaires à l'aide des micro-organismes ou de leur descendance.
EP16763271.0A 2016-09-12 2016-09-12 Micro-organismes et procédé de production de lactones et de leurs produits secondaires par conversion de cycloalcanes Pending EP3510164A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2016/071388 WO2018046104A1 (fr) 2016-09-12 2016-09-12 Micro-organismes et procédé de production de lactones et de leurs produits secondaires par conversion de cycloalcanes

Publications (1)

Publication Number Publication Date
EP3510164A1 true EP3510164A1 (fr) 2019-07-17

Family

ID=56893988

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16763271.0A Pending EP3510164A1 (fr) 2016-09-12 2016-09-12 Micro-organismes et procédé de production de lactones et de leurs produits secondaires par conversion de cycloalcanes

Country Status (2)

Country Link
EP (1) EP3510164A1 (fr)
WO (1) WO2018046104A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112457412A (zh) * 2020-11-26 2021-03-09 浙江工业大学 一种人工电子传递系统及其在促进p450酶羟基化反应中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020018729A1 (fr) * 2018-07-17 2020-01-23 Conagen Inc. Production biosynthétique de gamma-lactones
WO2020052762A1 (fr) 2018-09-13 2020-03-19 Helmholtz-Zentrum Für Umweltforschung Gmbh - Ufz Composition de micro-organismes photoautotrophes et de micro-organismes chimiohétéotrophes dans un biofilm
CN110938663B (zh) * 2019-11-30 2022-12-16 华南理工大学 一种基于改造核糖体结合位点提高ε-己内酯产量的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007060705A1 (de) 2007-12-17 2009-06-18 Evonik Degussa Gmbh ω-Aminocarbonsäuren oder ihre Lactame, herstellende, rekombinante Zellen
CN103732569B (zh) * 2011-06-17 2016-06-29 英威达技术有限责任公司 使用水解酶来增加废物流中的单体含量

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112457412A (zh) * 2020-11-26 2021-03-09 浙江工业大学 一种人工电子传递系统及其在促进p450酶羟基化反应中的应用

Also Published As

Publication number Publication date
WO2018046104A1 (fr) 2018-03-15

Similar Documents

Publication Publication Date Title
TWI567201B (zh) 己二酸（酯或硫酯）之合成技術
EP1483378B1 (fr) Systeme de recyclage permettant la manipulation de la disponibilite intracellulaire du nadh
US10961539B2 (en) Promoter system inducing expression by 3-hydroxypropionic acid and method for biological production of 3-hydroxypropionic acid using same
CA3005460A1 (fr) Expression fonctionnelle de monooxygenases et procedes d'utilisation
EP3510164A1 (fr) Micro-organismes et procédé de production de lactones et de leurs produits secondaires par conversion de cycloalcanes
WO2007061590A1 (fr) Production d'acide malique dans de la levure recombinant
TW201439325A (zh) 使羧酸酯反應之方法
US20150299741A1 (en) Method for conversion of an alkane or 1-alkanol to a diol
WO2012109534A2 (fr) Cellules et procédés de production d'acide isobutyrique
Prell et al. Adaptive laboratory evolution accelerated glutarate production by Corynebacterium glutamicum
KR20220023339A (ko) 조작된 트랜스아미나아제 및 제조 및 사용 방법
JP2017516470A (ja) ナイロンの製造方法
JP2021129603A (ja) ω−官能化カルボン酸及びそのエステルの生物工学的な製造
JP2014023528A (ja) 改変微生物及び該改変微生物を利用した１，４−ブタンジオールの生産方法
KR20230003072A (ko) 조작된 효소 및 이의 이용 및 제조 방법
WO2001068803A2 (fr) Enzymes, voies et organismes pour la fabrication d'un monomere polymerisable par un bioprocessus cellulaire integral
KR20240051254A (ko) 포르메이트 데하이드로게나제 변이체 및 이용 방법
US20200048639A1 (en) Culture modified to convert methane or methanol to 3-hydroxyproprionate
CN117604004A (zh) D-氨基酸氧化酶突变体、核酸分子、重组菌株及其应用
CN116376940A (zh) 一种表达d-氨基酸氧化酶的方法及其应用
TWI628282B (zh) 己二酸（酯或硫酯）之合成技術

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190325

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)